Prevalence and prognostic impact of retropharyngeal lymph nodes metastases in oropharyngeal squamous cell carcinoma: Meta-analysis of published literature.
Carcinoma, Squamous Cell
/ pathology
Head and Neck Neoplasms
/ pathology
Humans
Lymph Nodes
/ pathology
Lymphatic Metastasis
/ pathology
Oropharyngeal Neoplasms
/ pathology
Papillomavirus Infections
/ complications
Prevalence
Prognosis
Retrospective Studies
Squamous Cell Carcinoma of Head and Neck
/ pathology
HPV
human papillomavirus
oropharyngeal cancer
retropharyngeal lymph nodes
retropharyngeal metastasis
Journal
Head & neck
ISSN: 1097-0347
Titre abrégé: Head Neck
Pays: United States
ID NLM: 8902541
Informations de publication
Date de publication:
10 2022
10 2022
Historique:
revised:
12
07
2022
received:
23
03
2022
accepted:
15
07
2022
pubmed:
2
8
2022
medline:
9
9
2022
entrez:
1
8
2022
Statut:
ppublish
Résumé
This systematic review and meta-analysis aims to estimate the prevalence and prognostic impact of retropharyngeal lymph node metastases (RLNMs) in oropharyngeal squamous cell carcinoma (OPSCC). This meta-analysis was conducted according to PRISMA guidelines. studies with more than 20 patients reporting the prevalence or prognostic impact of RLNMs in OPSCC. Whenever available, data on HPV status and subsites were extracted. Twenty-two articles were included. The overall prevalence of RLNMs in OPSCC was 13%, with no significant differences depending on HPV status. The highest prevalence was observed for posterior pharyngeal wall SCC (24%), followed by soft palate (17%), palatine tonsil (15%), and base of tongue (8%). RLNMs were associated with a significantly higher risk of death (HR:2.54;IC95%1.89-3.41) and progression (HR:2.44;IC95%1.80-3.30). The prevalence of RLNMs in OPSCC was 13%, being higher in tumors of the posterior pharyngeal wall. RLNMs were associated with unfavorable outcomes.
Sections du résumé
BACKGROUND
This systematic review and meta-analysis aims to estimate the prevalence and prognostic impact of retropharyngeal lymph node metastases (RLNMs) in oropharyngeal squamous cell carcinoma (OPSCC).
METHODS
This meta-analysis was conducted according to PRISMA guidelines.
INCLUSION CRITERIA
studies with more than 20 patients reporting the prevalence or prognostic impact of RLNMs in OPSCC. Whenever available, data on HPV status and subsites were extracted.
RESULTS
Twenty-two articles were included. The overall prevalence of RLNMs in OPSCC was 13%, with no significant differences depending on HPV status. The highest prevalence was observed for posterior pharyngeal wall SCC (24%), followed by soft palate (17%), palatine tonsil (15%), and base of tongue (8%). RLNMs were associated with a significantly higher risk of death (HR:2.54;IC95%1.89-3.41) and progression (HR:2.44;IC95%1.80-3.30).
CONCLUSIONS
The prevalence of RLNMs in OPSCC was 13%, being higher in tumors of the posterior pharyngeal wall. RLNMs were associated with unfavorable outcomes.
Identifiants
pubmed: 35913029
doi: 10.1002/hed.27166
pmc: PMC9540534
doi:
Types de publication
Journal Article
Meta-Analysis
Review
Systematic Review
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2265-2276Informations de copyright
© 2022 The Authors. Head & Neck published by Wiley Periodicals LLC.
Références
Head Neck. 2017 Oct;39(10):1969-1975
pubmed: 28758272
Cancer. 2019 May 1;125(9):1536-1546
pubmed: 30620385
World J Surg Oncol. 2010 Aug 16;8:70
pubmed: 20712875
Arch Otolaryngol Head Neck Surg. 2000 Dec;126(12):1478-81
pubmed: 11115286
Radiology. 2010 May;255(2):605-12
pubmed: 20413770
Radiother Oncol. 2020 Jan;142:92-99
pubmed: 31431388
Radiother Oncol. 2013 Nov;109(2):293-6
pubmed: 24103114
Eur J Radiol. 2014 Jul;83(7):1157-1162
pubmed: 24736007
PLoS One. 2019 Jul 29;14(7):e0220534
pubmed: 31356646
Cancer. 2014 Dec 15;120(24):3994-4002
pubmed: 25143048
Int J Radiat Oncol Biol Phys. 2016 Mar 15;94(4):775-82
pubmed: 26972650
Laryngoscope. 2013 Jul;123(7):1676-81
pubmed: 23371397
BMJ. 2021 Mar 29;372:n71
pubmed: 33782057
Cancer. 2013 Sep 1;119(17):3162-9
pubmed: 23733178
Otolaryngol Head Neck Surg. 2009 Nov;141(5):633-8
pubmed: 19861203
Head Neck. 2022 Oct;44(10):2265-2276
pubmed: 35913029
Cancer Treat Rev. 2016 Jan;42:24-9
pubmed: 26547133
J Clin Epidemiol. 2016 Jul;75:40-6
pubmed: 27005575
Oral Oncol. 2014 Nov;50(11):1109-13
pubmed: 25200523
Int J Cancer. 2017 Aug 15;141(4):664-670
pubmed: 28369882
Head Neck. 1995 May-Jun;17(3):190-8
pubmed: 7782203
Oral Oncol. 2011 Aug;47(8):758-62
pubmed: 21680228
Laryngoscope. 2015 Nov;125(11):2503-8
pubmed: 26227748
Cancer Commun (Lond). 2018 May 9;38(1):20
pubmed: 29764509
Stat Med. 1999 Feb 15;18(3):321-59
pubmed: 10070677
Dentomaxillofac Radiol. 2015;44(3):20140126
pubmed: 25430557
J Otolaryngol. 1978 Dec;7(6):528-36
pubmed: 569713
J Clin Epidemiol. 2001 Oct;54(10):1046-55
pubmed: 11576817
BMC Cancer. 2012 Jun 18;12:253
pubmed: 22708791
Ann Surg Oncol. 2015 Sep;22(9):3049-54
pubmed: 25608771
Int J Radiat Oncol Biol Phys. 2006 Jul 1;65(3):733-8
pubmed: 16751061
Head Neck. 2011 Oct;33(10):1520-9
pubmed: 20737485
Cureus. 2019 Jan 4;11(1):e3825
pubmed: 30868038
BMC Med Imaging. 2020 Jul 29;20(1):88
pubmed: 32727384
JAMA Otolaryngol Head Neck Surg. 2016 Apr;142(4):313-8
pubmed: 26892642
Radiology. 1983 Sep;148(3):709-14
pubmed: 6878691
Radiother Oncol. 2021 Feb;155:174-181
pubmed: 33069764
Radiother Oncol. 2015 Jul;116(1):75-81
pubmed: 26094074
Arch Otolaryngol Head Neck Surg. 2004 Feb;130(2):169-73
pubmed: 14967745
Acta Otolaryngol Suppl. 2007 Dec;(559):123-8
pubmed: 18340583
Int J Radiat Oncol Biol Phys. 2019 Aug 1;104(5):1017-1027
pubmed: 30953712
Head Neck. 2019 Feb;41(2):398-402
pubmed: 30552839
Head Neck. 2016 Apr;38 Suppl 1:E981-6
pubmed: 26040490
Br J Oral Maxillofac Surg. 2019 Jul;57(6):515-528
pubmed: 31076218
Nucl Med Commun. 2010 Mar;31(3):260-5
pubmed: 20072075
Acta Otolaryngol. 2006 Aug;126(8):872-7
pubmed: 16846932
J Craniofac Surg. 2019 Jan;30(1):145-148
pubmed: 30480635
Eur Arch Otorhinolaryngol. 2021 Oct;278(10):3995-4004
pubmed: 33417147
Int J Radiat Oncol Biol Phys. 2006 Jul 1;65(3):739-44
pubmed: 16751062